FY2025 · ended Dec 31, 2025 · Revenue $66.58M, +19.7% YoY · Filed Mar 10, 2026
Exagen Inc. (XGN) files with the SEC under industry code 8071, Services-Medical Laboratories. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $66.6 million and a net loss of $20.0 million. Free cash flow was -$14.3 million. As of Jun 30, 2026 it held $24.6 million in cash and investments and $27.7 million in total debt.
Revenue (TTM)
$71.12M
+20.8% vs year-ago TTM
Net income (TTM)
$-18.92M
-11.4% vs year-ago TTM
Operating cash flow (TTM)
$-6.50M
+57.7% vs year-ago TTM
Free cash flow (TTM)
$-7.59M
+52.5% vs year-ago TTM
EPS (TTM)
$-0.80
+10.0% vs year-ago TTM
Dividend per share
None
Shares outstanding
24.05M
+34.4% vs prior year
Net cash
$-3.07M
as of Jun 30, 2026
Operating margin
-18.6%
FY 2026
Company profile
- Industry
- Services-Medical Laboratories (SIC 8071)
- Listed as
- XGN (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Vista, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1274737
- Former names
- EXAGEN DIAGNOSTICS INC (until May 18, 2017)
Other Services-Medical Laboratories companies
- Natera, Inc. NTRA
- Labcorp Holdings Inc. LH
- Quest Diagnostics Inc DGX
- Guardant Health, Inc. GH
- Caris Life Sciences, Inc. CAI
- GRAIL, Inc. GRAL
- RadNet, Inc. RDNT
- BillionToOne, Inc. BLLN
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $66.6M | $55.6M | $52.5M | $45.6M | $48.3M |
| Operating income | -$14.1M | -$13.6M | -$22.8M | -$46.1M | -$24.1M |
| Net income | -$20.0M | -$15.1M | -$23.7M | -$47.4M | -$26.9M |
| Diluted EPS | -$0.93 | -$0.83 | -$1.34 | -$2.77 | -$1.68 |
| Operating cash flow | -$13.6M | -$13.3M | -$14.5M | -$32.1M | -$20.3M |
| Free cash flow | -$14.3M | -$13.8M | -$15.3M | -$36.5M | -$22.6M |
| Total assets | $58.0M | $44.7M | $56.9M | $86.2M | $123.4M |
| Total liabilities | $40.6M | $35.1M | $34.2M | $43.8M | $38.5M |
| Stockholders' equity | $17.4M | $9.5M | $22.7M | $42.5M | $84.9M |
| Cash and investments | $32.2M | $22.0M | $36.5M | $62.4M | $99.4M |
| Total debt | $27.7M | $23.4M | $24.1M | $36.0M | $27.5M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Aug 4, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 4, 2026 | Aug 4, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 9, 2026 | Jun 9, 2026 |
| 10-Q | Quarterly report | May 11, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 11, 2026 | May 11, 2026 |
| ARS | Annual report to shareholders | Apr 27, 2026 | Dec 31, 2025 |
All 421 Exagen Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.